All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The management of plaque psoriasis during pregnancy is not well understood. The Summaries of Product Characteristics (SmPC) for biologics recommend discontinuation during pregnancy, and most should be stopped up to 24 weeks prior to conception. Only certolizumab pegol may be used in pregnancy if appropriate. In France, official guidelines follow the recommendations of the SmPCs; however, practitioners may not always follow these recommendations.
Here, we summarize a study by Tran et al.1 published in Annales of Dermatology and Venereology on the real-life practice of dermatologists in the management of pregnant women with psoriasis treated with biologics.
Figure 1. Management strategies of practitioners for biologic use in psoriasis during pregnancy*
SmPC, Summaries of Product Characteristics.
*Adapted from Tran, et al.1
†The SmPC for biologics recommend discontinuation during pregnancy and should be stopped up to 24 weeks prior to conception.
|
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox